1874. Adherence to Practice Guidelines for Treating Diabetic Foot Infections: An Opportunity for Syndromic Stewardship
Session: Poster Abstract Session: Antimicrobial Stewardship: Potpourri
Saturday, October 6, 2018
Room: S Poster Hall

Adherence to the Infectious Diseases Society of America (IDSA) guidelines for the treatment of diabetic foot infections (DFIs) has been associated with improved outcomes. Yet, compliance with these guidelines has been reported to be low. We initiated a quality improvement project aimed at improving guideline adherence for DFI management. Baseline results are reported here.


We reviewed all hospitalized primary DFIs newly initiated on antibiotics over 1 year (7/14-6/15). We collected demographics, DFI severity per IDSA guidelines, antibiotic use, and microbiology data. Guideline adherence for culturing and empiric antibiotic choice (based on severity) was assessed per IDSA guidelines. We then created an institutional guideline and electronic order set with built-in clinical decision support. Educational lectures on DFI best practices were given to providers who commonly treat DFIs.


177 DFI admissions were identified: 40% severe (n=70), 47% moderate (n=84), 8% mild (n=14) and 5% with no evidence of infection (n=9). Demographics: mean age 58 years; 68% male, mean HgbA1c 8.6%, length of stay 6.9 days, three-year mortality 13%. Empiric antibiotic regimens were judged inappropriate in 36% (64/177) of cases. The most common reason for inappropriate antibiotic use was unnecessary coverage for Pseudomonas aeruginosa in 50% (54/107) of non-severe cases. In 28% (39/140) of cases with an ulcer, wound or skin breakdown, a superficial swab culture was obtained which is inappropriate. Only 33.3% (n=56) had a deep tissue culture obtained. In patients with deep tissue cultures, methicillin-resistant Staphylococcus aureus (MRSA) was found in 11% (6/56) of cases but covered for empirically in 88% (50/56). Pseudomonas was found in 2% (1/56) of cases but covered for empirically in 73% (41/56).


MRSA and Pseudomonas are uncommon DFI pathogens yet are frequently treated empirically. Inappropriate antibiotic use is often due to empiric coverage for Pseudomonas in non-severe DFIs where it is a rare pathogen. Culture practices are also less than ideal with frequent superficial swabs and underutilization of deep cultures. Institutional guidelines were developed to specifically address these issues and data collection of the impact of this project is in process.

Randy McCreery, MD, Infectious Diseases, University of Nebraska Medical Center, Omaha, NE, Scott Bergman, PharmD, FIDSA, FCCP, BCPS, Department of Pharmaceutical Care, Nebraska Medicine, Omaha, NE and Trevor Vanschooneveld, MD, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, NE


R. McCreery, None

S. Bergman, Merck: Grant Investigator , Grant recipient .

T. Vanschooneveld, Merck: Grant Investigator , Grant recipient .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.